Showing results (351-360 of 981) with videos related to
Sort By:
Pageof 99
Cardiovascular Therapeutics|September 3, 2011
Overexpression of vasostatin-1 protects hypoxia/reoxygenation injuries in cardiomyocytes independent of endothelial cellsMin Yu, Zheng Wang, Yue Fang, et al.Cardiovascular Therapeutics|September 3, 2011
Ginsenoside Re: pharmacological effects on cardiovascular systemLu Peng, Shi Sun, Lai-Hua Xie, et al.Cardiovascular Therapeutics|September 3, 2011
Additive effect of homocysteine- and cholesterol-lowering therapy on endothelium-dependent vasodilation in patients with cardiovascular diseaseKerstin Wustmann, Marco Klaey, Annika Burow, et al.Cardiovascular Therapeutics|September 3, 2011
Metabolic antianginal agent ranolazine offers good symptom relief in a patient with inoperable severe aortic stenosisPandula Athauda-Arachchi, Chim LangCardiovascular Therapeutics|September 3, 2011
Trimetazidine reduces endogenous free fatty acid oxidation and improves myocardial efficiency in obese humansMarco Bucci, Ronald Borra, Kjell Någren, et al.Cardiovascular Therapeutics|September 3, 2011
Matricellular proteins: new molecular targets to prevent heart failureHiroshi Okamoto, Kyoko Imanaka-YoshidaCardiovascular Therapeutics|September 3, 2011
Chronic pretreatment of metformin is associated with the reduction of the no-reflow phenomenon in patients with diabetes mellitus after primary angioplasty for acute myocardial infarctionJing-Lin Zhao, Chao-Mei Fan, Yue-Jin Yang, et al.Cardiovascular Therapeutics|September 3, 2011
Is angiotensin-converting enzyme inhibitor a contraindication for contrast-induced nephropathy prophylaxis? A review about its paradoxXiming Li, Tingting Li, Hongliang CongCardiovascular Therapeutics|November 13, 2010
Thrombolytics and myocardial infarctionVijayalakshmi Kunadian, C Michael GibsonCardiovascular Therapeutics|October 5, 2011
Do statins have a role in reduction/prevention of post-PCI restenosis?Kailash PrasadPageof 99